Logo
x

Search

Subscribe Now

Tonix Pharmaceuticals

Tonix Pharmaceuticals Publishes P-III Results of TNX-102 SL in Military-Related PTSD in Psychiatry Research

Tonix Pharmaceuticals Publishes P-III Results of TNX-102 SL in Military-Related PTSD in Psychiatry Research

  • March 8, 2024
Tonix Pharmaceuticals’ IND Application for TNX-2900 Receives the US FDA’s Approval for the Treatment of Prader-Willi Syndrome (PWS)

Tonix Pharmaceuticals’ IND Application for TNX-2900 Receives the US FDA’s Approval for the Treatment of Prader-Willi Syndrome (PWS...

  • December 5, 2023
Tonix Pharmaceuticals Reports the Results for TNX-102 SL in P-III Trial for the Management of Fibromyalgia

Tonix Pharmaceuticals Reports the Results for TNX-102 SL in P-III Trial for the Management of Fibromyalgia

  • November 16, 2023
Tonix Pharmaceuticals Reports the Completion of Patient Enrollment in NDA-Enabling P-III Trial (RESILIENT) of TNX-102 SL for Fibromyalgia

Tonix Pharmaceuticals Reports the Completion of Patient Enrollment in NDA-Enabling P-III Trial (RESILIENT) of TNX-102 SL for Fibro...

  • August 2, 2023
Tonix Pharmaceuticals to Acquire Zembrace SymTouch and Tosymra from Upsher-Smith Laboratories for Acute Migraine

Tonix Pharmaceuticals to Acquire Zembrace SymTouch and Tosymra from Upsher-Smith Laboratories for Acute Migraine

  • June 27, 2023
Tonix Pharmaceuticals Receives the US FDA’s IND Clearance of TNX-1500 for the Prevention of Organ Rejection in Kidney Transplant Patients

Tonix Pharmaceuticals Receives the US FDA’s IND Clearance of TNX-1500 for the Prevention of Organ Rejection in Kidney Transplant P...

  • May 5, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.